Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Net Income (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Net Income for 3 consecutive years, with -$2.8 million as the latest value for Q4 2025.

  • Quarterly Net Income fell 42.12% to -$2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$20.6 million through Dec 2025, down 137.08% year-over-year, with the annual reading at -$20.6 million for FY2025, 137.08% down from the prior year.
  • Net Income hit -$2.8 million in Q4 2025 for Mangoceuticals, up from -$7.6 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$1.8 million in Q3 2023 to a low of -$7.6 million in Q3 2025.
  • Historically, Net Income has averaged -$3.2 million across 3 years, with a median of -$2.5 million in 2023.
  • Biggest five-year swings in Net Income: grew 24.12% in 2024 and later tumbled 281.0% in 2025.
  • Year by year, Net Income stood at -$2.6 million in 2023, then increased by 24.12% to -$1.9 million in 2024, then crashed by 42.12% to -$2.8 million in 2025.
  • Business Quant data shows Net Income for MGRX at -$2.8 million in Q4 2025, -$7.6 million in Q3 2025, and -$5.4 million in Q2 2025.